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SUMMARY
Abetalipoproteinemia (ABL) is an inherited disor-
der of lipoprotein metabolism resulting from muta-
tions in microsomal triglyceride transfer protein
(MTTP). In addition to expression in the liver and
intestine, MTTP is expressed in cardiomyocytes,
and cardiomyopathy has been reported in several
ABL cases. Using induced pluripotent stem cells
(iPSCs) generated from an ABL patient homozy-
gous for a missense mutation (MTTPR46G), we
show that human hepatocytes and cardiomyo-
cytes exhibit defects associated with ABL dis-
ease, including loss of apolipoprotein B (apoB)
secretion and intracellular accumulation of lipids.
MTTPR46G iPSC-derived cardiomyocytes failed
to secrete apoB, accumulated intracellular lipids,
and displayed increased cell death, suggesting
intrinsic defects in lipid metabolism due to loss
of MTTP function. Importantly, these pheno-
types were reversed after the correction of the
MTTPR46G mutation by CRISPR/Cas9 gene editing.
Together, these data reveal clear cellular defects
in iPSC-derived hepatocytes and cardiomyocytes
lacking MTTP activity, including a cardiomyocyte-
specific regulated stress response to elevated
lipids.
INTRODUCTION
Abetalipoproteinemia (ABL) is an autosomal-recessive disorder
caused by mutations in the gene MTTP, which encodes the
endoplasmic reticulum (ER)-resident lipid transfer protein micro-
somal triglyceride transfer protein (MTTP). MTTP functions to
promote lipid transfer to apolipoprotein B (apoB) within the ER,
facilitating its secretion by the enterocyte and hepatocyte (Wet-
terau et al., 1990, 1991). Genetic deficiency in MTTP results in
undetectable apoB-containing lipoproteins in plasma due to
the inability to secrete them. While hepatic steatosis is a known
complication of ABL, primary hepatocytes from patients with
ABL have never been characterized.
Both MTTP and apoB are expressed in human and mouse
heart tissue, suggesting that the heart has the capacity to
secrete lipoproteins (Bore´n et al., 1998; Nielsen et al., 1998,
1999). Mttp null mice have elevated triglyceride stores in the
heart (Bjorkegren et al., 2001). However, it is not known whether
cardiac lipid metabolism is affected in patients with ABL. Inter-
estingly, some patients with ABL disease exhibit cardiac arrhyth-
mias and heart failure (Dische and Porro, 1970; Gregg and Wet-
terau, 1994; Ledmyr et al., 2004; Sobrevilla et al., 1964; Zamel
et al., 2008). These findings are consistent with the concept
that MTTP-mediated secretion of apoB is a possible mechanism
for protecting against cardiomyocyte lipid overload.
In order to define the cell-intrinsic roles for MTTP in hepa-
tocytes and cardiomyocytes, induced pluripotent stem cells
were generated from an ABL patient and control subjects
and differentiated into hepatocytes and cardiomyocytes. As
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expected, ABL induced pluripotent stem cell (iPSC) hepatocytes
failed to secrete apoB and accumulated lipids. Interestingly,
compared with control iPSC cardiomyocytes, iPSC cardiomyo-
cytes from the ABL patient failed to secrete apoB, accumulated
intracellular lipids, and responded poorly after stress induction
through increased apoptosis. These data provide evidence
that MTTP in human cardiomyocytes facilitates lipid export,
leading to protection from cellular stress in the setting of lipid
overload.
RESULTS
Generation of MTTPR46G-Specific and Control iPSCs
We generated iPSCs from an ABL patient homozygous for a rare
missense mutation in the MTTP gene (136C > G) and matched
control subjects using standard procedures (Yang et al., 2012).
This missense mutation occurs in the N-terminal region of
MTTP, causing an amino acid switch from arginine to glycine
at residue 46 (MTTPR46G) (Figures S1A and A1B). Clinically, the
patient with the MTTPR46G mutation had undetectable plasma
apoB, very low plasma cholesterol and triglyceride levels (Table
S1), steatorrhea, microvesicular steatosis, spinocerebellar
degeneration, and retinopathy, all consistent with classic ABL
(Miller et al., 2014; Walsh et al., 2015; Zeissig et al., 2010). Three
different iPSC lines were established from this patient and con-
trol subjects (Table S2). These iPSCs expressed high levels of
pluripotency markers, including NANOG, OCT4, and SOX2 (Fig-
ure S1C). Quantitative flow cytometry demonstrated over 90%of
the MTTPR46G iPSCs express the cell-surface pluripotency
markers SSEA-4 and TRA-1-60 (Figure S1D).
Recapitulation of the ABL Phenotype in Mutant
MTTPR46G Hepatocytes
To determine the effect of the MTTPR46G mutation on apoB
secretion in hepatocytes, we differentiated MTTPR46G and con-
trol iPSCs into hepatocytes using a standard protocol (Si-Tayeb
et al., 2010). After 20 days, the majority of the differentiated cells
from control and MTTPR46G iPSCs were positive for the hepato-
cyte markers HNF4a and ASGPR1 (Figure S2A). Expression of
hepatic genes, including ALB, AFP, HNF4a, and ASGPR1,
were at levels similar to those of the hepatic cell line Huh7 (Fig-
ure S2B). Additionally, functional synthesis and secretion of al-
bumin were equivalent between control and MTTPR46G hepato-
cytes (Figures S2C and S2D).
Hepatocytes derived from MTTPR46G iPSCs expressed levels
of the MTTP gene and MTTP protein comparable to those of
differentiated hepatocytes from control iPSCs (Figures 1A and
1B). However, as shown in Figure 1C, lysate from control hepa-
tocytes displayed triglyceride transfer in an MTTP activity assay,
whereas lysate from the MTTPR46G iPSC hepatocytes had no
detectable MTTP activity (Figure 1C). Thus, the MTTPR46G muta-
tion abolishedMTTP triglyceride transfer activity, consistent with
the phenotypes of ABL in the patient. The apoB mRNA level was
normal in MTTPR46G hepatocytes, but there was an almost com-
plete absence of intracellular and extracellular secreted apoB
protein (Figures 1D–1F). Because poorly lipidated apoB is known
to undergo proteasomal degradation (Fisher et al., 1997; Yeung
et al., 1996), we inhibited this process with N-acetyl-leucyl-
leucyl-norleucinal (ALLN) (Sakata and Dixon, 1999). After a 1-hr
pre-treatment with ALLN followed by a 20-min pulse with 35S
methionine/cysteine, a significant amount of new apoB protein
was synthesized in MTTPR46G hepatocytes, whereas control
cells exhibited only a moderate elevation in newly synthesized
apoB, indicating substantial proteasomal degradation of apoB
in the mutant MTTPR46G hepatocytes (Figures 1G and 1H).
When these cells were chased in label-free media, control cells
exhibited a slower decrease in newly synthesized cellular apoB
levels that reached 30% of initial levels after a 120-min chase,
whereas MTTPR46G hepatocytes had a dramatic reduction in
apoB after just a 30-min chase, with only 9% of the initially
labeled protein remaining after a 60-min chase (Figure 1I).
Hepatosteatosis is commonly observed in both ABL and
mouse models representing loss of MTTP (Chang et al., 1999;
Raabe et al., 1999). We examinedwhether iPSC-derived hepato-
cytes from the MTTPR46G patient exhibited lipid accumulation as
assessed by Oil Red O staining. A significant amount of large
lipid droplets were observed in MTTPR46G hepatocytes, whereas
control cells were nearly free of large intracellular lipid droplets
(Figure 2A). This is supported by a quantitative increase in triglyc-
erides and cholesterol in MTTPR46G iPSC-derived hepatocytes
(Figures 2B and 2C). Oleic acid (OA) treatment, which stimulates
neutral lipid synthesis and secretion in hepatocytes, also re-
sulted in a significant increase in cellular triglyceride and choles-
terol levels in MTTPR46G-derived hepatocytes compared to con-
trol cells (Figures 2B and 2C). Labeling cells with [3H]-OA showed
that the increase in triglyceride (TG) from OA treatment was due
to defective secretion from hepatocytes (Figures 2D and 2E).
Taken together, MTTPR46G iPSC-derived hepatocytes exhibit
the hallmark features of ABL, including the absence of apoB
secretion, excess intracellular lipid storage, reduced hepatic
lipid secretion, and excess intracellular lipid storage, presumably
due to loss of MTTP lipid transfer activity.
Correction of the C136G Mutation inMTTP by Gene
Editing Rescues the ABL Phenotype in MTTPR46G
iPSC-Derived Hepatocytes
We corrected MTTP C136G mutation causing the R46G mutant
using a CRISPR/Cas9 gene editing approach (Figure 3A) (Ran
et al., 2013). We obtained two clones bearing the corrected allele
as confirmed by DNA sequencing (Figure 3B). These corrected
iPSC lines expressed similar levels of pluripotency markers as
well as hepatocyte markers upon differentiation (Figures 3C
and 3D). Newly synthesized apoBwas examined in the corrected
lines using [35S] methionine/cysteine 2-hr labeling experiments.
In contrast to the mutant MTTPR46G line, levels of cellular and
secreted apoB were mostly or partially normalized by the gene
correction, indicating that the MTTPR46G mutation caused the
decrease in apoB stability in hepatocytes (Figures 3E–3G).More-
over, Oil Red O staining revealed a decrease in lipid droplet
accumulation in the differentiated hepatocytes from the cor-
rected line in comparison to the MTTPR46G line (Figure 3H).
Cardiomyocyte-Intrinsic Defects due to Expression of
the MTTPR46G Protein
While liver and intestine are the major sites ofMTTP expression,
human and mouse heart also expresses MTTP proteins (Nielsen
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et al., 1998). However, the role MTTP plays in cardiac lipid
metabolism remains unclear. To examine the role of MTTP
in human cardiomyocytes, we differentiated both control and
MTTPR46G iPSCs into cardiomyocytes using a previously pub-
lished protocol (Laflamme et al., 2007; Shiba et al., 2012).
Synchronic beating from induced cardiomyocytes was observed
in control, MTTPR46G, and corrected lines by day 14 of dif-
ferentiation. All cells expressed equivalent levels of cardiomyo-
cyte markers, including MYH6, MYH7, MLC2a, and MLC2v
(Figure S3).
Similar levels of MTTP mRNA and MTTP protein were
observed in control, MTTPR46G, and correction cardiomyocytes
(Figures S4A and S4B). We next examined the effect of lipid
loading on all cell lines. Interestingly, both OA and palmitic acid














































































































































Figure 1. Abolished apoB Secretion in
Mutant MTTPR46G Differentiated Hepato-
cytes
(A and B) Quantification of messenger RNA of
MTTP (A) and MTTP protein (B) by real-time PCR
and western blot, respectively.
(C) Microsomal TG transfer activity wasmeasured.
(D and E) Quantification of messenger RNA (D) and
protein (E) of apoB 100 by real-time PCR and
western blot, respectively.
(F) ApoB protein secreted into media after a 16-hr
incubation was measured by ELISA.
(G) Newly synthesized cellular apoB was analyzed
by immunoprecipitation and SDS-PAGE after a
20-min label with [35S]methionine/cysteine in the
presence or absence of ALLN.
(H) Quantification of newly synthesized apoB
protein with normalization to albumin after a
20-min pulse with [35S]methionine/cysteine.
(I) Pulse-chase of newly synthesized apoB for 30,
60, and 120 min. Graph shows the percentage
relative to initial amount of apoB at the end of the
label.
*p < 0.05 **p < 0.01. Values are means of three
independent experiments.
rected cells (Figure 4A). However, apoB
secretion was only detectable in control
cardiomyocytes and the gene-corrected
line, whereas MTTPR46G cells had little
to no detectable apoB secretion after
OA or PA treatment (Figure 4B). OA and
PA treatment also induced increased
neutral lipid accumulation in MTTPR46G
compared to control cardiomyocytes
(Figures 4C, 4D, and S4C), which is
further supported by a significant in-
crease in TG synthesis in MTTPR46G-
derived cardiomyocytes (Figure 4E). This
also led to a decrease in secreted TGs
in theMTTPR46G-derived cardiomyocytes
(Figure 4F). While the amounts of apoB
and TG secreted are dramatically lower
in cardiomyocytes than in hepatocytes,
there was still a significant decrease observed in MTTPR46G rela-
tive to control cardiomyocytes. In addition, the TG:CE (choles-
teryl ester) ratio of lipids secreted from cardiomyocytes and
hepatocytes differs, suggesting less TG-rich particles produced
by cardiomyocytes (Figure S4D). This is consistent with the pre-
vious findings that the apoB-containing lipoproteins secreted
from mouse and human hearts are not TG rich but rather
have a density consistent with a more cholesterol-rich low-den-
sity lipoprotein (LDL) particle (Bore´n et al., 1998). Correction
of the R46G mutation restored apoB and TG secretion and
lipid accumulation to those of control cardiomyocyte levels
(Figures 4B–4F). These results demonstrate that human cardio-
myocytes require MTTP for secretion of apoB and lipid and in
the setting of genetic MTTP deficiency are vulnerable to lipid
accumulation.
1458 Cell Reports 19, 1456–1466, May 16, 2017
Hypersensitivity of MTTPR46G Cardiomyocytes to
Metabolic Stresses
Altered metabolism of free fatty acids and lipid accumulation
in the myocardium can cause myocardial dysfunction and cardi-
omyocyte apoptosis (Chiu et al., 2001; Christoffersen et al.,
2003). Increased cardiac apoB secretion has been shown to
ameliorate cardiac dysfunction in dietary and genetic mouse
models of lipid overload (Bartels et al., 2009; Yokoyama et al.,
2004). Therefore, we examined whether loss of MTTP function
altered the response of mutant MTTPR46G cardiomyocytes to
multiple metabolic stresses. MTTPR46G and control cells treated
with sunitinib, a receptor tyrosine kinase inhibitor that has car-
diac cytotoxicity (Force and Kolaja, 2011; Orphanos et al.,
2009), exhibited a similar dose-dependent increase in apoptosis
(Figures S5A and S5B). However, when sunitinib was added
in the presence of PA to induce lipid synthesis, a significant
increase in apoptosis, evaluated by TUNEL and cleaved cas-
pase-3 staining, was noted inMTTPR46G cardiomyocytes relative
to control cells (Figures 5A–5D). The increased apoptosis in
MTTPR46G cardiomyocytes was normalized to control levels
with correction of the MTTPR46G mutation (Figures 5A–5D).
These results suggest an overload of intracellular lipid content
reduces the tolerance toward the combined effects of multiple
pharmacological stressors in MTTPR46G cells.
We next tested cardiomyocytes stress tolerance with hypoxia
followed by reoxygenation, another metabolic stressor that is













































































Figure 2. Accumulated Lipid Droplets in Mutant
MTTPR46G Differentiated Hepatocytes
(A) Representative images of lipid droplets stained with
oil red O. Yellow arrowheads indicate red positive lipid
stains. Hematoxylin stains the nuclei blue.
(B and C) Cellular TG (B) and total cholesterol (TC)
(C) content was determined by enzymatic assays and
normalized to total cellular protein asmeasured by BCA
assay.
(D andE)Cellswere incubatedwith [3H ]-OA(5 mCi/mL) +
0.8mMOA for 4 hr. Cellular (D) andmedium (E) TGwere
extracted, separated by TLC, and quantified by liquid
scintillation counting. TG counts are normalized to
protein contents determined by Lowry protein assay
(n = 4).
*p < 0.05 Values are means for three independent
experiments. Scale bar, 400 mm.
used as an in vitro model of ischemia reper-
fusion (IR) injury. Cells were subjected to
PA, hypoxia and reoxygenation (H/R), or
H/R+PA treatment. While H/R+PA triggered
an apoptotic response in all cell lines, a
more pronounced response was noted in
MTTPR46G cells relative to controls (Figures
5E and 5F). This differential sensitivity in
MTTPR46G cardiomyocytes to H/R+PA was
normalized in the gene-corrected line (Fig-
ures 5E and 5F). This suggests PA-induced
overload of intracellular lipid in cardiomyo-
cytes sensitizes stress responses to multiple
metabolic stresses. Expression of genes
associated with cardiac dysfunction and failure was significantly
higher in MTTPR46G cardiomyocytes than in control cardiomyo-
cytes after treatment of sunitinib together with PA (Figure 6A).
However, correction of the MTTP C136G mutation normalized
the expression of genes after PA treatment, suggesting a protec-
tive role of MTTP during lipid-induced stresses in cardiomyo-
cytes. ANP and BNP expression was also significantly upregu-
lated in MTTPR46G cells after hypoxic treatment, suggesting a
protective role of MTTP in cardiomyocytes. Importantly, hypoxic
stress was normalized by correction of the MTTP C136G muta-
tion (Figure 6B).
DISCUSSION
The present study uses patient-specific iPSCs generated from a
patient with ABLwith amissensemutation (MTTPR46G) in both al-
leles of the MTTP gene. Differentiation of the iPSCs to hepato-
cytes produced the expected phenotype of abolished apoB
production and accumulation of intracellular lipid, phenotypes
that were corrected by genome editing of the causal MTTP mu-
tation. Moreover, cardiomyocytes derived from the ABL iPSCs
displayed impaired apoB secretion, lipid accumulation, and
increased sensitivity to cellular stress. These results are consis-
tent with a role for MTTP in promoting secretion of apoB in hepa-
tocytes and cardiomyocytes and protecting cardiomyocytes
from cellular stress.







Figure 3. Correction of C136G in MTTP Rescues the ABL Phenotype
(A) Schematic strategy for correction of C136G in MTTP by CRISPR/Cas9.
(B) An iPSC from an ABL patient was transfected with plasmids containing guide RNA and Cas9. Genomic DNAwas extracted fromGFP+ colonies and subjected
to PCR amplification. Subsequent DpnII digestion was applied to identify the positively targeted clones.
(C) The corrected iPSC lines were tested for expression of pluripotency markers by real-time PCR.
(D) Expression of hepatic genes was analyzed by real-time PCR in hepatocytes derived from the corrected iPSC lines.
(E–G) Amount of newly synthesized apoB in the cell or secreted in the medium was measured at the end of a 2-hr label with [35S]methionine/cysteine.
(F) Autoradiography for apoB in the media.
(H) Cellular lipid accumulation by oil red O staining following rescue of the C136G MTTP mutation by CRISPR/Cas9. Scale bar, 400 mm.
*p < 0.05. **p < 0.01. Values are means ± SD from three independent experiments.
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Anumber ofmutations inMTTP have been identified that result
in the ABL phenotype (Miller et al., 2014; Shoulders et al., 1993;
Walsh et al., 2015). Many of these mutations lead to premature
stop codons or defective splicing and result in reduced or absent
expression of a full-length MTTP protein (Pons et al., 2011).
Other missense mutations are not predicted to affect the TG
transfer function of MTTP and may act through different mecha-
nisms to cause ABL phenotypes (Al-Shali et al., 2003; Ohashi
et al., 2000; Wang and Hegele, 2000). While there are several
mouse models to study the function of MTTP, none of these
examine the effect of human missense mutations (Bartels
et al., 2009; Chang et al., 1999; Liang et al., 2014; Raabe et al.,
1999; Tietge et al., 1999). Our studies clearly establish that the
missensemutation MTTPR46G abolishes MTTP activity and reca-
pitulates the ABL phenotype, making the patient-specific iPSCs
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Figure 4. Abolished apoB and Elevated Lipid
Storage upon Fatty Acid Treatment in Cardi-
omyocytes Was Rescued by Correction of
MTTPR46G
(A and B) ApoB transcript (A) and medium (B) apoB
protein upon fatty acids treatment were quantified
by real-time PCR and ELISA, respectively. Cells
were incubated with oleic acid (OA; 1 mM) or pal-
mitic acid (PA; 0.5 mM) for 48 hr.
(C) Representative images of neutral lipid staining in
cardiomyocytes. Cardiac troponin T stains cardiac
muscle fiber proteins green. Nile red stains lipid
droplet red. DAPI stains nuclei blue.
(D) Mean fluorescence intensity of Nile red was
analyzed by ImageJ. Fold relative to control is
shown.
(E and F) Newly synthesized cellular TG content is
quantified in cardiomyocytes (E) and in the culture
media (F) following a 24-hr label with [14C] oleic acid
and lipid extraction. TG counts are normalized
to protein contents determined by Lowry protein
assay.
*p < 0.05. Values are means for three independent
experiments. Scale bar, 25 mm.
MTTP plays a critical role in intracellular
assembly of apoB-containing TG-rich lipo-
proteins in both liver and intestine (Young,
1990). The MTTP gene is expressed not
only in the intestine and liver but also
in the heart (Berriot-Varoqueaux et al.,
2000; Hussain et al., 2012). Expression
and secretion of apoB lipoproteins has
been demonstrated from human heart bi-
opsy specimens (Bore´n et al., 1998; Niel-
sen et al., 1998, 1999). However, the phys-
iological role of this cardiac expression
and secretion of lipoproteins remains to
be determined. A role for MTTP in promot-
ing secretion of apoB in the human heart
has been previously proposed to protect
the heart against toxic load of lipid accu-
mulation (Bartels et al., 2009). Heart-specific MTTP knockout
mice had elevated cardiac TG levels (Bjorkegren et al., 2001).
Although cardiac expression of MTTP is low (Aminoff et al.,
2010), its expression increases in the ischemic myocardium.
Interestingly, reduced myocardial expression ofMTTP in hypox-
ic hearts is associated with increased myocardial lipid (Ledmyr
et al., 2004; Nielsen et al., 2002). A genetic variant associated
with reducedMTTP expression is associated with increased car-
diac disease (Ledmyr et al., 2004). In addition, cardiomyopathy,
arrhythmias, cardiomegaly, and cardiac failure have been
described in ABL patients, though the patient in our study did
not present with obvious cardiomyopathy (Dische and Porro,
1970; Sobrevilla et al., 1964; Zamel et al., 2008). While the etiol-
ogy of myopathy is unclear in these cases, it could be related to
muscle weakness caused by vitamin E deficiency resulting from
lack of absorption in intestine. Our studies reveal a cardiomyo-
cyte-intrinsic phenotype due to loss of MTTP activity, which
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Figure 5. MTTPR46G Cardiomyocytes Are Hypersensitive to Metabolic Stresses
(A) Representative images showing sunitinib (15 mM) and PA (0.5mM) induced apoptosis as visualized by TUNEL-positive cells (green). DAPI stains nuclei blue.
(B) Percentage of sunitinib-induced TUNEL positivity was quantified by cell counting using ImageJ (>1,000 nuclei were counted per genotype).
(C) Representative images showing expression of cleaved caspase-3 in sunitinib- and PA-treated cardiomyocytes. Troponin T, green; cleaved caspase-3, red;
and DAPI, blue.
(D) Mean fluorescence density for cleaved caspase-3 was quantified using ImageJ. Fold change relative to control is shown.
(legend continued on next page)
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may be critical in the setting of lipid overload. In particular, upon
fatty acid treatment, apoB can be clearly detected in control car-
diomyocytes and the conditioned media, whereas ABL cardio-
myocytes had absent secreted apoB, lipid accumulated in the
cell, and increased cellular TG levels. This leads to increased
sensitivity to cytotoxic stresses, ultimately resulting in increased
apoptosis in lipid-overloaded cardiomyocytes as well as
increased sensitivity to hypoxia and rexoygenation. Together,
our data suggest that low-level secretion of lipidated apoB by
cardiomyocytes serves a different physiological function—not
bulk secretion of lipids but rather secretion of particular lipids.
Furthermore, this pathway in cardiomyocytes may not be
physiologically relevant, except in times of stress and/or lipid
overload. Importantly, the phenotypes we observed in both
MTTPR46G hepatocytes and cardiomyocytes were rescued by
CRISPR/Cas9-mediated gene correction. This strongly supports
the contention that these phenotypes are due to the mutation in
MTTP. Our studies provide new evidence to support a physio-
logical role for MTTP expression in human cardiomyocytes to
export apoB and excess lipid and protect the heart from stress.
Our studies reveal that coupling rigorous iPSC differentiation
protocols for multiple cell lineages as well as gene correction al-
lows for the discovery and analysis of new phenotypes caused
by rare genetic mutations. Although our studies are limited to
cells from one ABL patient, this human disease iPSC/CRISPR/
Cas9 model allows for further resolution of the complex disease
phenotype in ABL patients and favors for the development of
therapies directed toward this rare genetic disorder as well as
potentially other causes of cellular lipotoxicity.
EXPERIMENTAL PROCEDURES
Human Subjects
All human studies were approved by the University of Pennsylvania Human
Subjects Research Institutional Review Board. The individuals were specif-
ically recruited for this study and gave their informed written consent. The
study was conducted at the Perelman School of Medicine at the University
of Pennsylvania. Peripheral blood samples obtained from the subjects were
used for general lipid measurements as well as generation of iPSC lines. See
Table S1 for gender, age, and race of individuals used in this study.
Generation of Subject-Specific iPSCs and Differentiation into
Hepatocytes and Cardiomyocytes
Subject-specific peripheral blood mononuclear cell (PBMC)-derived iPSCs
were generated using Sendai viral vectors by the iPSC Core Facility at Univer-
sity of Pennsylvania as previously described (Yang et al., 2012, 2015). These
cell lines have been deposited at WiCell Research Institute (http://www.
wicell.org/home/stem-cell-lines/catalog-of-stem-cell-lines/collections/nhlbi-
next-gen-rader.cmsx). The hepatocytes and cardiomyocytes were generated
from iPSCs using standard protocols described previously (Cai et al., 2008;
Laflamme et al., 2007; Mallanna and Duncan, 2013; Shiba et al., 2012).
ApoB Labeling
20 days after initiation of differentiation, newly synthesized apoB in iPSC-
derived hepatocytes was labeled and traced using methods described previ-
ously (Yamaguchi et al., 2006). In brief, immunoprecipitation of proteins from
each sample was carried out using antibodies against apoB (Calbiochem) or
albumin (Sigma). Cell lysates or conditioned medium was mixed with NET
buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris [pH 7.4], 0.5% Triton X-100,
and 0.1% SDS) and an excess amount of various antisera. The mixture was
incubated at 4C for 1 hr. Protein A-agarose was added to the reaction solu-
tion, and the incubation was continued for additional 16 hr. The beads were
washed with NET buffer, and proteins were released with sample buffer
(0.125 M Tris-HCl [pH 6.8], 4% SDS, 20% glycerol, and 10% b-mercaptoetha-
nol) by boiling for 5 min. Samples were resolved by gel electrophoresis fol-
lowed by autoradiography. The total amount of apoB100 in the cell or media
was normalized to the total amount of albumin protein in each sample.
ApoB Pulse-Chase Assay
Newly synthesized apoB was traced using the method described previously
(Yamaguchi et al., 2006). Briefly, iPSC-derived hepatocytes were preincu-
bated in serum-free DMEM without methionine/cysteine containing 1.5%
BSA with or without 40 mg/mL ALLN (Calpain Inhibitor 1, Sigma) for 1 hr and
then labeled with DMEM without methionine/cysteine containing 1.5% BSA
with or without ALLN and 200 mCi/ml [35S]methionine/cysteine for 20min. After
being washed, cells were incubated in serum-free DMEM plus 1.5% BSA con-
taining 10 mM methionine and 3 mM cysteine for 10 or 120 min. The medium
was collected, and cells were lysed at 10, 40, 70, or 130 min.
In other experiments, hepatocytes were preincubated for 1 hr and labeled
with 150 mCi/mL [35S]methionine/cysteine for 2 hr, after which media was
collected and cells were lysed. The lysis buffer contained 62.5 mM sucrose,
0.5% sodium deoxycholate, 0.5% Triton X-100, 50 mM Tris-HCl (pH 7.4),
150 mM NaCl, 50 mg/mL leupeptin, 50 mg/mL pepstatin A, and 30 mL/mL pro-
tease inhibitor mixture (1 mM benzamidine, 5 mM EDTA, 100 U/mL aprotinin,
and 10 mM HEPES [pH 8.0]). Conditioned medium was mixed with protease
inhibitor mixture and 0.86 mM freshly made phenylmethylsulfonyl fluoride.
Cell lysates and conditioned medium were used for immunoprecipitations.
TG and Total Cholesterol Measurement
Total TG and cholesterol contents were measured by enzymatic assays and
normalized to protein as measured by bicinchoninic acid assay (BCA) (Bi
et al., 2014). Briefly, iPSC-derived hepatocytes and cardiomyocytes were
pretreated with or without OA or PA for 24 hr. Cells were washed with PBS,
and pellets were obtained from centrifugation. Cell membrane was removed
by sonication in RIPA buffer. Total TG and cholesterol contents were deter-
mined by enzymatic assays and normalized to protein as measured by BCA
assay (Kohan et al., 2012). To measure newly synthesized TGs, cells were
preincubated with [3H]-OA (5 mCi/mL) in the presence of OA (0.8 mM) for
4 hr. To measure radiolabeled TG, lipids were extracted from medium and
cells, fractionated by thin-layer chromatography (TLC), and quantified by
scintillation spectroscopy. TG counts in cell and medium were normalized to
total cellular protein (Chung et al., 2010)
MTTP Lipid Transfer Activity Assay
MTTP lipid transfer activity in iPSC-derived hepatocytes was determined using
a method described previously (Athar et al., 2004).
Genome Editing by CRISPR/Cas9
Precise gene correction was performed by CRISPR/Cas9 following a pub-
lished protocol (Ran et al., 2013). Briefly, single guide RNAs (sgRNAs) were
designed using the MIT CRISPR Design Tool and cloned into the plasmid
PX458 (Addgene plasmid ID: 48138). ssODNs were suspended in sterile
H2O and transfected into iPSCs using 4D-Nucleofector (Lonza) together with
PX458-sgRNA. The nucleofected iPSCs were plated with mTeSR1 supple-
mented with 2 mM Thiazovivin (Sigma). After 24 hr, GFP+ cells were sorted
(E) Quantification of TUNEL positivity in response to hypoxia and reoxygenation and PA.
(F) Representative images showing expression of cleaved caspase-3 in hypoxia and reoxygenation- and PA-treated cardiomyocytes. Troponin T, white; cleaved
caspase-3, green; Nile red, red; and DAPI, blue. Graph to the right shows mean fluorescence density for cleaved caspase-3 (quantified using ImageJ). Fold
change relative to control is shown.
*p < 0.05. Values are means ± SD from three independent experiments. Scale bar represents 150 mm (A) and 40 mm (C).
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by FACSJazz (BD). Single GFP+ iPSCs were maintained in mTeSR1 and
allowed to grow into colonies until manually picking for DNA extraction
with Quick Extract DNA Extraction Solution (Epicentre). Then, DNA was sub-
jected to PCR amplification around the cutting site and subsequent DpnII
(New England Biolabs) digest to analyze successfully edited clones.
Lipid Droplet Staining
Oil red O (Sigma, O0625) and Nile red (Thermo Fisher Scientific) were used to
label lipid droplets in iPSC-derived hepatocytes and cardiomyocytes accord-
ing to the manufacturer’s instructions. iPSC-derived hepatocytes were fixed
with 4% paraformaldehyde for 15 min, followed by incubation with distilled
water and subsequently with 60% isopropanol for 2 min and stained with
a filtered 0.35% Oil Red O (Sigma) solution in 60% isopropanol for 10 min
at room temperature. Then, cells were washed with sterile water and stained
with hematoxylin solution for 1 min at room temperature. Images were
analyzed under a light microscope. Lipid droplets appear red and nuclei
appear blue.
To stain neutral lipids in iPSC-derived cardiomyocytes, cells at 20 days were
treated with OA or PA separately for 24 hr. Fixation and permeabilization
were performed using the samemethod as described above. Cardiomyocytes
were co-stained with cardiac troponin T (Thermo Fisher Scientific) and Nile
Red (Thermo Fisher Scientific), followed with Alexa 488 (Invitrogen). Images
were acquired by confocal microscopy (Leica TCS SP8). Cardiac troponin T
protein stains green, lipid droplets appear red, and nuclei stains blue.
TUNEL Assay
Cardiomyocytes derived from iPSCswere treatedwith sunitinib (0, 1.5 mM, and
15 mM) with or without palmitate (0.5 mM) for 18 hr. Cells were then fixed to
determine apoptosis using the In Situ Cell Death Detection Kit (Roche,
11684795910) according to the manufacturer’s protocol. Briefly, cells were
fixed and permeabilized using the method described above. Cells were
labeled with TUNEL enzyme mixture in a humidified environment at 37C for
1 hr. DAPI solution was applied to stain total nuclei. Fluorescence microscopy
































































































































































































































Figure 6. Increased Expression of Stress Response Genes in MTTPR46G Cardiomyocytes
(A) Expression of stress associated genes, such as Caspase3, Caspase9, Bak, ANP, BNP, Hsp32, and HSP70-2 in response to sunitinib (SU) and PA by real-
time PCR.
(B) Expression of stress genes, including Caspase3, p53, ANP, and BNP, in response to H/R and PA.
*p < 0.05. Values are means ± SD from three independent experiments.
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appear blue. Both nuclei were counted and calculated as the percentage of
apoptotic index. Over 500 cells were counted in test samples.
Cleaved Caspase-3 Assay
Cardiomyocytes derived from iPSCs were treatedwith sunitinib (15 mM)with or
without palmitate (0.5 mM) for 18 hr. Cells were then fixed and permeabilized
for cleaved caspase-3. Cardiomyocytes were co-stained with cleaved cas-
pase-3 (Cell Signaling) and cardiac troponin T (Thermo Fisher Scientific), fol-
lowed by a second antibody staining with Alexa 488 (Invitrogen) and Alexa
Fluor 555. Images were acquired with a Leica microscope. Cardiac troponin
T protein stains green, cleaved caspase-3 stains red, and nuclei stains blue.
Hypoxia and Reoxygenation Stress Assay
iPSC-derived cardiomyocytes were maintained in serum-free medium with or
without palmitate followed by exposure to hypoxia (94% N2, 5% CO2, and 1%
O2) for 18 hr. Cells were then moved back to an environment with 20% O2
(5% CO2) for reoxygenation. After 24 hr, cells were fixed for analysis of TUNEL
or cleaved caspase-3 (Portal et al., 2013).
ELISA
Levels of albumin (Bethyl Laboratories) and apoB (Mabtech) in the medium
were determined using commercial ELISA kits.
Statistical Analysis
Data were analyzed for statistical significance using a two-tailed unpaired
Student’s t test (GraphPad Prism). p values less than 0.05 were considered
statistically significant. All quantitative data are presented as mean ± SD.
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